4 drug(s) with this reaction
8,671 total reports
Febrile Neutropenia has been reported as an adverse reaction across 4 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 8,671 adverse event reports mention febrile neutropenia in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with febrile neutropenia, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have febrile neutropenia listed in their FDA adverse event reports, sorted by report count:
In addition to febrile neutropenia, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
4 drug(s) manufactured by Amgen Inc have febrile neutropenia listed in their FDA adverse event reports: FILGRASTIM, PEGFILGRASTIM, PANITUMUMAB, BLINATUMOMAB.
There are a combined 8,671 reports of febrile neutropenia across 4 Amgen Inc drug(s) in the FDA adverse event database.